BioNTech SE

Latest Results (29.08.2026):

BioNTech SE’s financial results for the second quarter of 2026 (Q2 2026) show a sharp revenue decline versus the year-ago period and a substantially larger net loss as the company invests heavily in R&D and commercial build‑up while absorbing acquisition and prioritization-related charges. Q2 2026 revenue was €105.6 million (Q2 2025: €260.8 million) and net loss was €820.8 million IFRS (€562.3 million adjusted). Year-to-date figures through June 30, 2026 show revenues of €223.7 million and an IFRS net loss of €1,352.7 million (adjusted net loss €1,056.9 million). The company also revised full‑year 2026 revenue guidance downward and reaffirmed a strong cash position supporting ongoing investment and a $1.0 billion share repurchase program.

Revenue

Q2 2026 revenues: €105.6 million (vs. €260.8 million in Q2 2025). Year-to-date June 30, 2026: €223.7 million (vs. €443.6 million prior). Decline primarily driven by lower demand for COVID‑19 vaccines.

Profitability — Net Loss and EPS

Q2 2026 net loss (IFRS): €820.8 million; adjusted net loss: €562.3 million. Q2 diluted loss per share: €3.24 (IFRS) and €2.22 (adjusted). Year-to-date IFRS net loss: €1,352.7 million; adjusted: €1,056.9 million. YTD diluted loss per share: €5.34 (IFRS) and €4.17 (adjusted).

R&D and SG&A Spend

Q2 2026 R&D: €551.0 million (Q2 2025: €509.1M). Q2 adjusted R&D (ex impairments): €477.1M. YTD R&D: €1,108.0M (adjusted YTD: €1,004.2M). Q2 SG&A: €197.8 million (vs. €137.4M), YTD SG&A: €348.6M (vs. €258.0M). Spend increases reflect late‑stage pipeline advancement, pre‑launch/commercial build-up, CureVac inclusion and prioritization costs.

Other Operating Items and Adjustments

Q2 2026 other operating result: negative €207.9 million (vs. negative €39.0M prior year). Q2 adjusted other operating result: negative €23.3 million (ex employee‑related costs and impairments). Impairments and pipeline prioritization actions materially affected IFRS results.

Balance Sheet and Liquidity

Cash, cash equivalents and security investments at June 30, 2026: €16,634.2 million (cash & equivalents €9,741.0M; current securities €5,035.1M; non‑current securities €1,858.1M). Shares outstanding: 251,204,366 (excluding 7,823,121 treasury shares).

Share Repurchase Program

BioNTech launched a repurchase program of up to $1.0 billion (through May 6, 2027). In Q2 2026 the company repurchased 1,693,056 ADSs at an average $89.50 (€77.85) for total consideration of $151.6 million (€131.8M).

Revised 2026 Guidance

Revenue guidance (revised Aug 2026): €1,600–€1,900 million (previously €2,000–€2,300M). Reasons: softer COVID‑19 vaccine demand, use of existing German inventory, and delayed milestone revenue from an out‑licensed R&D program. BioNTech expects a majority of 2026 revenue in H2 and anticipates recognizing €613 million BMS collaboration revenue in Q3.

Planned Adjusted Expense Ranges

Adjusted R&D guidance revised to €2.0–€2.3 billion (previously €2.2–€2.5B). Adjusted SG&A guidance remains €700–€800 million. Company cites prioritization and cost discipline to generate savings going forward.